TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7623249

Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) root conditioning and fibrin-fibronectin sealing system (FFSS) application
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control treatment with gingival flap surgery with barrier membrane alone
Number of subjects: 8
Study: 2533041

Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 779058

Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 mg tilidine hydrochloride
Number of subjects: 40
Study: 30540657

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 360

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study: 28121722

Group type: EXPERIMENTAL
Intervention: 1000 mg of EPA and 400 mg of DHA per day for 18 weeks
Number of subjects: 272

Group type: COMPARATOR
Intervention: Soybean oil capsules (placebo) per day for 18 weeks
Number of subjects: 272
Study: 25654366

Group type: EXPERIMENTAL
Intervention: Home-based telehealth hospitalization
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional hospitalization
Number of subjects: 57
Study: 24634944

Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (no phlebotomy)
Number of subjects: 92
Study: 21205302

Group type: EXPERIMENTAL
Intervention: Masihambisane intervention (peer mentor-led sessions)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard care PMTCT control condition
Number of subjects: 1200
Study: 18503652

Group type: EXPERIMENTAL
Intervention: Total body relaxation
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Jaw relaxation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study: 17119709

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 12
Study: 14514592

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.75 pmol x kg(‐1) x min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 8
Study: 11590117

Group type: EXPERIMENTAL
Intervention: Elevated perceptual thresholds for left/right outward radial optic flow discrimination in AD patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation of elevated optic flow thresholds with visuospatial function tests
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Global pattern perceptual deficits
Number of subjects: 36
Study: 9748131

Group type: EXPERIMENTAL
Intervention: Nonradiolabeled 3F8
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 131I-labeled 3F8 (8-28 mCi/kg) with autologous bone marrow rescue
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both nonradiolabeled and 131I-labeled 3F8
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 3F8 treatment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: GD2 expression
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: GD2 expression persistence
Number of subjects: 95
Study: 8040406

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for 2 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 2493756

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (2 mg per dose) by MDI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo by MDI
Number of subjects: 32
Study: 1097921

Group type: EXPERIMENTAL
Intervention: Acupuncture at standard acupuncture points
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment at placebo points
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 40
Study: 31567321

Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope
Number of subjects: 367

Group type: COMPARATOR
Intervention: Optiscope video stylet
Number of subjects: 367
Study: 30045159

Group type: EXPERIMENTAL
Intervention: Pharmacy claims adherence (PDC)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: GlowCap adherence (GC)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Combination of PDC and GC adherence
Number of subjects: 682

Group type: COMPARATOR
Intervention: PDC alone
Number of subjects: 682
Study: 29184630

Group type: EXPERIMENTAL
Intervention: Envelope flap (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Triangular flap (Group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 25
Study: 24643755

Group type: EXPERIMENTAL
Intervention: DHA-enriched beverage
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23219310

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 500mg orally twice daily for 28 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 9
Study: 21787080

Group type: EXPERIMENTAL
Intervention: Written communication tool to facilitate doctor-patient communication
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Written communication tool
Number of subjects: 180
Study: 19567121

Group type: EXPERIMENTAL
Intervention: Tri-duct plus tri-structure method
Number of subjects: 10492

Group type: COMPARATOR
Intervention: Tri-duct method
Number of subjects: 10492
Study: 16779983

Group type: EXPERIMENTAL
Intervention: Physician-patient counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written literature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational video
Number of subjects: 0
Study: 15569037

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Promethazine 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naltrexone and Promethazine
Number of subjects: 12
Study: 11568132

Group type: EXPERIMENTAL
Intervention: High-altitude warm (HW) training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-altitude warm training
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-altitude cool training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-altitude cool training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-altitude warm training
Number of subjects: 20
Study: 9418642

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy, local irradiation, limb salvage surgery, prophylactic whole lung irradiation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Local irradiation of the affected site
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Histologic response to preoperative multidisciplinary therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Prophylactic whole lung irradiation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 130
Study: 31713082

Group type: EXPERIMENTAL
Intervention: Dextrose injection (1% lidocaine with 20% dextrose, 1 mL)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline injection (1% lidocaine with saline, 1 mL)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (Dextrose and Saline)
Number of subjects: 49
Study: 28029114

Group type: EXPERIMENTAL
Intervention: 400 µg folic acid and 500 µg vitamin B12 supplementation
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo (non-supplemented group)
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Plasma homocysteine
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Serum vitamin B12
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Holotranscobalamin
Number of subjects: 2919
Study: 25011384

Group type: EXPERIMENTAL
Intervention: Combination exercise group
Number of subjects: 110

Group type: COMPARATOR
Intervention: All exercise modes
Number of subjects: 110
Study: 23020192

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) cohort
Number of subjects: 37049

Group type: COMPARATOR
Intervention: Non-CKD cohort
Number of subjects: 37049

Group type: EXPERIMENTAL
Intervention: CKD cohort
Number of subjects: 37049

Group type: EXPERIMENTAL
Intervention: CKD cohort (elderly)
Number of subjects: 37049

Group type: EXPERIMENTAL
Intervention: CKD cohort (youngest group)
Number of subjects: 37049

Group type: EXPERIMENTAL
Intervention: CKD cohort with alcoholism
Number of subjects: 37049

Group type: EXPERIMENTAL
Intervention: CKD cohort taking benzodiazepines
Number of subjects: 37049
Study: 19190821

Group type: EXPERIMENTAL
Intervention: Haplotype Gly16-Gln27-Thr164
Number of subjects: 25224

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25224
Study: 16720159

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Surgery first
Number of subjects: 143
Study: 15158621

Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment
Number of subjects: 22
Study: 11563205

Group type: EXPERIMENTAL
Intervention: In-home assessment with individualized treatment plan including exercise program
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: In-home assessment with individualized treatment plan including exercise program (for subjects with more than 2 falls in the 3 months preceding study entry)
Number of subjects: 163
Study: 9756110

Group type: EXPERIMENTAL
Intervention: Clozapine (CLZ)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Desmethylclozapine (DMCLZ)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clozapine/Desmethylclozapine ratio in plasma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clozapine/Desmethylclozapine ratio in saliva
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clozapine (CLZ) and Desmethylclozapine (DMCLZ) saliva concentrations
Number of subjects: 34
Study: 7529693

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) 75 units
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3043949

Group type: EXPERIMENTAL
Intervention: Isoconazole cream, solution, and spray (once or twice daily)
Number of subjects: 372
Study: 31271072

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fish protein hydrolysate (FPH)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study: 31641001

Group type: EXPERIMENTAL
Intervention: CBT-informed resiliency class (B-RICH+)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Depression QI alone
Number of subjects: 100
Study: 27670154

Group type: EXPERIMENTAL
Intervention: Daily dose of cholecalciferol (400 IU)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Single high-dose cholecalciferol (50,000 IU)
Number of subjects: 70
Study: 25548315

Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention programme with regular check-ups and a coaching approach
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nurse-led approach with personal relationship and coaching
Number of subjects: 15

Group type: COMPARATOR
Intervention: General preventive advice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Practical support
Number of subjects: 15
Study: 23616547

Group type: EXPERIMENTAL
Intervention: Self-evaluations in the social domain
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Self-evaluations in the academic domain
Number of subjects: 27
Study: 21477053

Group type: EXPERIMENTAL
Intervention: Sex under the influence of drugs or alcohol
Number of subjects: 37

Group type: COMPARATOR
Intervention: No influence of drugs or alcohol
Number of subjects: 37
Study: 19055791

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) morning dose at 8:00
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) pre-dinner dose at 17:00
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) evening dose at 22:00
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 16769438

Group type: EXPERIMENTAL
Intervention: Audio Computer-Assisted Self-Interview (ACASI)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Interviewer‐Administered Questionnaire (IAQ)
Number of subjects: 268
Study: 15612863

Group type: EXPERIMENTAL
Intervention: Higher levels of suicide intent
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Accurate expectations about the likelihood of dying
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Degree of suicide intent
Number of subjects: 180
Study: 11887831

Group type: EXPERIMENTAL
Intervention: Estrogen therapy and SERMs (raloxifene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 9228376

Group type: EXPERIMENTAL
Intervention: Early extubation (7 to 11 hours postoperatively) - Group A (201 patients)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Conventional extubation (between 8 and 12 AM the following day) - Group B (203 patients)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Early extubation - Group A
Number of subjects: 404

Group type: COMPARATOR
Intervention: Conventional extubation - Group B
Number of subjects: 404
Study: 8077324

Group type: EXPERIMENTAL
Intervention: Low insulin infusion (742 +/- 212 pmol/L)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High insulin infusion (3360 +/- 710 pmol/L)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both insulin infusions
Number of subjects: 7
Study: 3608350

Group type: EXPERIMENTAL
Intervention: Torasemide 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Torasemide 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Torasemide (intermediate dose between 10 and 20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Probenecid pretreatment with Torasemide 20 mg
Number of subjects: 8
Study: 30299202

Group type: EXPERIMENTAL
Intervention: TCZ-SC qw monotherapy
Number of subjects: 0
Study: 28695373

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation with an additional linear lesion at the roof of the left atrium (group A)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation without an additional linear lesion at the roof of the left atrium (group B)
Number of subjects: 250
Study: 24325547

Group type: EXPERIMENTAL
Intervention: Immediate nonfunctional loading
Number of subjects: 21

Group type: COMPARATOR
Intervention: Delayed loading (control)
Number of subjects: 21
Study: 23701202

Group type: EXPERIMENTAL
Intervention: Coadministration of CQ (600 mg on days 1-2, 300 mg on day 3) and TQ (450 mg on days 2 and 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TQ alone (450 mg on days 2 and 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CQ alone (600 mg on days 1-2, 300 mg on day 3)
Number of subjects: 0
Study: 21778609

Group type: EXPERIMENTAL
Intervention: Low‐UV: UV irradiation from a distance of 10 cm for 10 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High‐UV: UV irradiation from a distance of 1 cm for 3 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control: No surface treatment
Number of subjects: 12
Study: 19712032

Group type: EXPERIMENTAL
Intervention: Academic detailing by the AUT
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control group (indication‐based guidelines for prescription of broad‐spectrum antimicrobials)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Feedback from the AUT alone
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Feedback from both the AUT and the infectious diseases consultation service
Number of subjects: 784
Study: 16542207

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol sustained release every 12 h for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 15145633

Group type: EXPERIMENTAL
Intervention: Rectal artesunate (single dose of about 10 mg/kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Parenteral quinine (10 mg/kg at 0, 4, and 12 h)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rectal artesunate and parenteral quinine
Number of subjects: 144
Study: 11180036

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg) coadministration with Sirolimus (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sirolimus (10 mg) alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem (120 mg) alone
Number of subjects: 18
Study: 9597123

Group type: EXPERIMENTAL
Intervention: IL-1Ra treatment for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant human IL-1Ra
Number of subjects: 0
Study: 8199179

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat-enriched (Poly) diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Step 1 diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Average American diet (AAD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Step 1 diet and Poly diet (Study B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Postprandial lipid and lipoprotein concentrations
Number of subjects: 8
Study: 2452393

Group type: EXPERIMENTAL
Intervention: Combined chemo‐radiotherapy (2 x COPP + ABVD + 20 Gy EF)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 x COPP + ABVD)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Induction chemotherapy (3 x COPP + ABVD) with consolidation by radiotherapy (20 Gy IF)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Including salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 x CEVD in case of persisting disseminated disease)
Number of subjects: 373
Study: 30974039

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (100 U in 10 points in the distal part of the esophageal wall)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 23
Study: 28642211

Group type: EXPERIMENTAL
Intervention: Multi-component care model combining collaborative care, decision-support, and population health management.
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Multi-component care model.
Number of subjects: 404
Study: 25550338

Group type: EXPERIMENTAL
Intervention: methotrexate monotherapy followed by add-on therapy with sulfasalazine and hydroxychloroquine
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: methotrexate monotherapy followed by add-on therapy with infliximab
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: initial methotrexate therapy
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: anti-CCP antibodies
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: anti-cVim antibodies
Number of subjects: 316
Study: 25462702

Group type: EXPERIMENTAL
Intervention: Artiss® fibrin glue plus drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (drainage alone)
Number of subjects: 60
Study: 21720885

Group type: EXPERIMENTAL
Intervention: Eccentric exercise in the ipsilateral arm (n = 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eccentric exercise in the contralateral arm (n = 8)
Number of subjects: 15
Study: 19615804

Group type: EXPERIMENTAL
Intervention: AST‐120 (6 g/d)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (low-protein diet and antihypertensive medication)
Number of subjects: 460
Study: 17714419

Group type: EXPERIMENTAL
Intervention: Full applied tension (AT) procedure
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Lower body tension
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Upper body tension
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Donation as usual (control group)
Number of subjects: 1209
Study: 15131439

Group type: EXPERIMENTAL
Intervention: Experimental discography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Psychometric profiles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not undergoing discography)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subset with somatization disorder in injection group
Number of subjects: 50
Study: 11741827

Group type: EXPERIMENTAL
Intervention: 0.6 ppm NO(2) for 3 h with intermittent moderate exercise
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.5 ppm NO(2) for 3 h with intermittent moderate exercise
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NO(2) exposure
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.5 ppm NO(2) exposure
Number of subjects: 21
Study: 9818106

Group type: EXPERIMENTAL
Intervention: 125 mg ropivacaine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 187.5 mg ropivacaine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 250 mg ropivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: 125 mg bupivacaine
Number of subjects: 52
Study: 7576417

Group type: EXPERIMENTAL
Intervention: Quasi-experimental designs (regression-discontinuity design and multiple interrupted time-series design)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized experiments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonequivalent group designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-experimental research
Number of subjects: 0
Study: 2651190

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg after dinner
Number of subjects: 304

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 304
Study: 319143

Group type: EXPERIMENTAL
Intervention: fenoterol (Th1165a)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ephedrine
Number of subjects: 28
Study: 30852011

Group type: EXPERIMENTAL
Intervention: High-fat CMR
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-lactose CMR
Number of subjects: 60
Study: 28937830

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg per day for 2 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 50